News Nippon Shinyaku Co., Ltd.

Equities

4516

JP3717600005

Delayed Japan Exchange Other stock markets 02:00:00 2024-04-25 am EDT			5-day change	1st Jan Change
4,307 ^JPY	+0.26%		+1.48%	-13.79%

Apr. 10	Jefferies Adjusts Nippon Shinyaku’s Price Target to 5,100 Yen From 6,900 Yen, Keeps at Buy	MT
Mar. 18	Nippon Shinyaku Co., Ltd.(TSE:4516) dropped from S&P Japan Mid Cap 100	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nippon Shinyaku : Submitted Additional Application of Uptravi® tablets 0.2 mg and 0.4 mg for the Treatment of Pediatric PAH and NDA of Pediatric 0.05 mg formulation to MHLW	Apr. 16	PU
Jefferies Adjusts Nippon Shinyaku’s Price Target to 5,100 Yen From 6,900 Yen, Keeps at Buy	Apr. 10	MT
MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases	Apr. 05	AQ
Nippon Shinyaku : Announcement of Research Alliance with MiNA Therapeutics in the Field of Central Nervous System	Apr. 04	PU
Final dividend	Mar. 27	FA
Nippon Shinyaku : UCB Japan Obtained Additional Application of Fintepla® (fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Japan	Mar. 26	PU
Nippon Shinyaku : Vyxeos® Combination for I.V. Injection Receives Approval for the Treatment of High-risk AML in Japan	Mar. 26	PU
Nippon Shinyaku : Announcement of Alliance Agreement for Pirtobrutinib, a Reversible Non-Covalent BTK Inhibitor in Japan	Mar. 25	PU
Nippon Shinyaku Co., Ltd.(TSE:4516) dropped from S&P Japan Mid Cap 100	Mar. 17	CI
VILTEPSO® (viltolarsen) injection: Phase II trial (Galactic53 trial) Data presented at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference	Mar. 06	PU
Year-end report 2023	Feb. 28	AQ
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate	Feb. 09	MT
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan	Feb. 09	AQ
Nippon Shinyaku : The European Commission Grants Orphan Drug Designation to NS-089/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy	Dec. 21	PU
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR Meeting (2Q FY2023)(Script+Q&A(Summary))P	Dec. 07	PU
Capricor Therapeutics Announces $23 Million Registered Direct Offering	23-10-02	AQ
Ex-dividend day for interim dividend	23-09-27	FA
The Menarini Group Announces ELZONRIS Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare	23-08-31	AQ
Jefferies Adjusts Nippon Shinyaku’s Price Target to 6,900 Yen From 6,700 Yen, Keeps at Buy	23-08-14	MT
Nippon Shinyaku Co., Ltd. Provides Earnings Guidance for the Fiscal Year 2023	23-08-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Nippon Shinyaku Co., Ltd.

Equities

4516

JP3717600005

Summary

Filters